Esperion Cholesterol

Esperion CholesterolEsperion Rises as Cholesterol Drug Can Forgo Heart Trial …
Esperion Therapeutics Inc. said U.S. regulators won't require a trial to determine the effects of its experimental cholesterol drug on heart health, smoothing the path toward approval.

Esperion drug succeeds in lowering LDL cholesterol -study …
Oct 1 A new type of experimental cholesterol fighter being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck & Co Inc's Zetia in a midstage clinical trial, the company said on Wednesday.

Hypercholesterolemia | Esperion Therapeutics
As members of the Esperion team developing ETC-1002—a unique, first-in-class, orally available, once-daily small molecule designed to lower low density lipoprotein cholesterol (LDL-C) levels, particularly in individuals with hypercholesterolemia who are intolerant to statins—we are excited …

LDL-C Lowering Therapies | Esperion Therapeutics
One year ago today the "new" Esperion re-entered the public markets with an initial public offering that raised $80 million and with a singular focus: to rapidly advance the development of ETC-1002, a unique, first-in-class, oral, once-daily low-density lipoprotein cholesterol (LDL-C …

Esperion Falls on Regulatory Setback for Cholesterol …
Esperion Therapeutics and the U.S. Food and Drug Administration failed to reach agreement on a definitive approval path for the company's cholesterol-lowering pill. Portola Pharmaceuticals, Esperion Therapeutics and Medicines were among the biotech stock movers in premarket trading on Friday

Esperion launches CVOT study of cholesterol fighter …
Thinly traded micro cap Esperion Therapeutics (ESPR +1.7%) perks up on more than triple normal volume, albeit on turnover of only 716K shares, in response to the initiation of a global cardiovascular outcomes trial (CVOT) assessing the effects of bempedoic acid on the occurrence of major CV events

Esperion Slumps on Lack of FDA Clarity for Cholesterol …
Esperion Therapeutics Inc. slumped as much as 29 percent in late trading after saying its experimental drug may not win Food and Drug Administration approval based solely on its ability to cut cholesterol, raising concerns it may take six more years to reach the U.S. market.

Cholesterol Drug Blues: Why Esperion Therapeutics' Stock …
Cholesterol Drug Blues: Why Esperion Therapeutics' Stock Is Getting Crushed Today Shares of Esperion Therapeutics cratered today. Here's why.

Esperion's Novel Approach To Lowering Cholesterol – Will …
Esperion's Novel Approach To Lowering Cholesterol – Will It Be Successful? … Esperion is led by Dr. Roger Newton, a scientific leader in the lipid lowering field. Roger was part of the team at Warner-Lambert that discovered the biggest selling drug of all time …

Esperion shares rally on cholesterol drug study – MarketWatch
Shares of Esperion Therapeutics rally after the drug developer said its treatment significantly lowered bad cholesterol in patients enrolled in a clinical trial.

FDA Cuts Limit on Esperion Cholesterol Drug, Considers …
As the FDA considers whether to approve two new cholesterol drugs with blockbuster potential, the agency also removed a "partial clinical hold" on the amo

Esperion drug lowers cholesterol in patients taking …
Esperion Therapeutics Inc said its experimental drug lowered LDL or "bad" cholesterol levels in patients who were already on statins, the current standard of care.

Esperion Therapeutics Announces Positive Top-Line Phase 2b …
Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002 Added to Stable Statin Therapy in Patients With Hypercholesterolemia

CNN.com – Pfizer to buy Esperion for $1.3bn – Dec. 21, 2003
NEW YORK (Reuters) –U.S. pharmaceuticals giant Pfizer says it has agreed to buy Esperion Therapeutics for about $1.3 billion, adding a promising experimental drug to its top selling line of cholesterol products.

Press Releases – Esperion Therapeutics, Inc.
The Investor Relations website contains information about Esperion Therapeutics, Inc. business for stockholders, potential investors, and financial analysts.

Experimental Cholesterol Drug Shows Effectiveness in Trial
Esperion Therapeutics said its experimental drug showed greater reductions in cholesterol levels when compared with a placebo in a mid-stage study.

Esperion Updates on its Cholesterol Management Candidate
Esperion Therapeutics, Inc. ESPR provided an update on end-of-phase II meeting with the FDA for its lipoprotein cholesterol (LDL-C) lowering therapy,.

Esperion Therapeutics' cholesterol drug successful in …
In a 348-patient Phase 2b clinical trial, Esperion Therapeutics' (ESPR-0.2%) product candidate for hypercholesterolemia, ETC-1002, achieved the primary endpoint of greater LDL-cholesterol lowering from baseline compared to ezetimibe.

Esperion drug shows promise in cutting cholesterol levels …
Esperion Therapeutics Inc.'s lead product in development boosted the effectiveness of drugs commonly used to lower levels of bad cholesterol in a mid-stage study, helping position it as another approach for fighting heart disease.

Esperion Therapeutics, Does Their Cholesterol-Reduction …
Esperion Therapeutics, Does Their Cholesterol-Reduction Drug Have "Blockbuster Potential"? Source: Life Science Leader

Esperion drug lowers cholesterol in patients taking …
By Amrutha Penumudi and Rosmi Shaji (Reuters) – Esperion Therapeutics Inc said its experimental drug lowered LDL or "bad" cholesterol levels in patients who were already on statins, the current standard of care.

Can Esperion Therapeutics Ever Regain Wall Street's Trust?
Esperion Therapeutics is developing a new drug that it says can lower LDL cholesterol, the bad kind associated with heart attacks, by 30%. But shares have fallen from a high of $98 last August to just $10 this morning as the regulatory future for its drug becomes increasingly muddy.

Esperion Update On Lead Cholestrol Drug Spooks Investors …
Worries Esperion Therapeutics is falling behind competitors in the race to bring the next generation of powerful cholesterol-lowering drug to market suddenly surfaced this week, sending the US biotech's share price plummeting more than 40% on Tuesday. Enter the email address associated with your

Esperion plans $150 million stock offering, stock soars on …
Following the release of positive results from human trials of its cholesterol drug this week, which sent its stock price rocketing in two days, Ann Arbor-based Esperion Therapeutics Inc. (Nasdaq: ESPR) has announced it intends a public offering of $150 million.

ESPR Stock Quote – Esperion Therapeutics Inc. Stock Price …
Esperion Therapeutics Inc. NASDAQ: ESPR GO. Set Alerts. Find a … Esperion Therapeutics stock price target cut to $15 from $30 at RBC Capital. … Esperion launches CVOT study of cholesterol fighter bempedoic acid; shares up 2%. 12:44 p.m. Jan. 9, …

Esperion Updates on its Cholesterol Management Candidate
Esperion Therapeutics, Inc. ESPR provided an update on end-of-phase II meeting with the FDA for its lipoprotein cholesterol (LDL-C) lowering therapy, ETC-1002.

Esperion CEO Twitter Trolls His Larger, Cholesterol …
Esperion CEO Twitter Trolls His Larger, Cholesterol-Lowering Rivals When a biotech CEO diverts from safe, bland corporate tweets to engage in some clever competitive trolling, I stand and applaud.

Esperion One-Ups Rival Cholesterol Drug in Midstage Study …
Esperion Therapeutics Inc (ESPR) hit a home run with top-line results from ETC-1002-008, a 12-week Phase 2b study that is one of the largest ever conducted with statin intolerant patients.

Esperion grooms cholesterol-cutting drug with new data …
A cholesterol-lowering pill from Esperion Therapeutics Inc., ETC-1002 (bempedoic acid), significantly reduced LDL-cholesterol levels vs. placebo in a phase IIb study of patients with hypercholesterolemia on stable statin therapy, answering a key question for potential partners ahead of a planned

Esperion drug succeeds in lowering LDL cholesterol -study
An experimental cholesterol-fighting drug being developed by Esperion Therapeutics Inc (Stuttgart: 0ET.SG – news) lowered LDL levels significantly more than Merck & Co Inc's Zetia in a midstage clinical trial, Esperion said on Wednesday. Esperion shares rose more than 40 percent in after-hours

Leave a Reply